PT  - JOURNAL ARTICLE
AU  - Kim Boesen
AU  - Peter C Gøtzsche
AU  - John PA Ioannidis
TI  - FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol)
AID  - 10.1101/2020.01.22.20018499
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.01.22.20018499
4099  - http://medrxiv.org/content/early/2020/01/27/2020.01.22.20018499.short
4100  - http://medrxiv.org/content/early/2020/01/27/2020.01.22.20018499.full
AB  - This is a protocol for the project entitled "FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials".Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will make available our full dataset on the Open Science Framework upon publication of the final report in a peer-reviewed medical journal. There may be restrictions on what we can share of documents obtained through the Freedom of Information Act requests.